Literature DB >> 10195869

Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.

O I Turhan1, N E Aydin, O Sariyüce, S Ozkan.   

Abstract

Prostatic epithelium basically consists of secretory-luminal, basal and endocrine-paracrine cells. Immunohistochemical procedures are frequently used for showing the cells reflecting different differentiations. In this study, 40 prostatic tissue specimens submitted to the Department of Pathology of Inönü University, Research Hospital, between 1991 and 1996 were examined. Half of the cases were diagnosed as cancer and the other half had various benign lesions. Of the cases 22.5% (n = 9) were needle biopsy material whereas the remainder, 47.5% (n = 19), were from prostatectomy and 30% (n = 12) were transurethral resection of the prostate (TURP) specimens. High molecular weight anti-cytokeratin antibodies (HMW anti-cytokeratin) stained basal cells both in all normal prostatic tissue and benign prostatic lesions, but in the majority of cancers (70%, n = 14) negative immunoreactivity was seen. Nevertheless, in some of the cancer cases (30%, n = 6) basal cell anti-cytokeratin staining was shown. Negative immunoreactivity with HMW anti-cytokeratin is important in distinguishing between malignant and benign lesions, whereas positive staining is not every time in favour of benign lesions. With the usage of prostate specific antigen (PSA) it was seen that all of the malignant and benign prostatic lesions stained positively. Basal cells in hyperplastic glands were not stained with this stain. Irregular, and in some areas, intense (PSA) immunoreactivity is present in precancerous and malignant lesions. Endocrine cells, which are represented with Chromogranin-A (Chr-A) immunoreactivity and reflecting neuroendocrine differentiation, are present in 75% (n = 15) of benign lesions and in 50% (n = 10) of cancer cases. It was thought that the lesser number of these cells in neoplastic lesions in comparison to the non-tumoral lesions is correlated with the disorder of mechanism that regulates the cell growth. Both in neoplastic and non-tumoral tissues the prostatic epithelial cells showed the three markers, namely HMW anti-cytokeratin, PSA, and Chr-A, which may reflect the multidirectional differentiation of these cells from a pluripotent origin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10195869     DOI: 10.1007/bf02564862

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  31 in total

1.  Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.

Authors:  L Hedrick; J I Epstein
Journal:  Am J Surg Pathol       Date:  1989-05       Impact factor: 6.394

2.  Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium.

Authors:  J G Azzopardi; D J Evans
Journal:  J Pathol       Date:  1971-08       Impact factor: 7.996

3.  A monoclonal antibody detecting neural and neuroendocrine differentiation.

Authors:  A P Sappino; R A McIlhinney; M Ellison; P Monaghan; A M Neville
Journal:  J Histochem Cytochem       Date:  1984-10       Impact factor: 2.479

4.  Basal cell adenoma of prostate.

Authors:  J I Lin; E L Cohen; A B Villacin; M B Garcia; C H Tseng
Journal:  Urology       Date:  1978-04       Impact factor: 2.649

5.  Mucin-secreting adenocarcinoma of the prostate with neuroendocrine differentiation and Paneth-like cells.

Authors:  W Van de Voorde; H Van Poppel; K Haustermans; L Baert; J Lauweryns
Journal:  Am J Surg Pathol       Date:  1994-02       Impact factor: 6.394

6.  Keratin immunoreactivity in the benign and neoplastic human prostate.

Authors:  M K Brawer; D M Peehl; T A Stamey; D G Bostwick
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

7.  Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.

Authors:  H Bonkhoff; U Stein; K Remberger
Journal:  Hum Pathol       Date:  1995-02       Impact factor: 3.466

8.  The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.

Authors:  K J Wojno; J I Epstein
Journal:  Am J Surg Pathol       Date:  1995-03       Impact factor: 6.394

Review 9.  Neuroendocrine differentiation in human prostatic carcinoma.

Authors:  P A di Sant'Agnese
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

10.  Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.

Authors:  A Berner; J M Nesland; H Waehre; J Silde; S D Fosså
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

View more
  1 in total

1.  EPN: a novel epithelial cell line derived from human prostate tissue.

Authors:  Antonio A Sinisi; Paolo Chieffi; Daniela Pasquali; Annamaria Kisslinger; Stefania Staibano; Antonio Bellastella; Donatella Tramontano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-03       Impact factor: 2.416

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.